Institutional Research Information Service
UCL Logo
Please report any queries concerning the funding data grouped in the sections named "Externally Awarded" or "Internally Disbursed" (shown on the profile page) to your Research Finance Administrator. Your can find your Research Finance Administrator at https://www.ucl.ac.uk/finance/research/rs-contacts.php by entering your department
Please report any queries concerning the student data shown on the profile page to:

Email: portico-services@ucl.ac.uk

Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
 More search options
Prof Paul Fish
Alzheimer's Research UK UCL Drug Discovery Institute
The Cruciform Building - Rm 1.3.06
Gower Street
Tel: +44 (0)20 7679 6971
Prof Paul Fish profile picture
  • Professorial Research Associate
  • Department of Neuromuscular Diseases
  • UCL Queen Square Institute of Neurology
  • Faculty of Brain Sciences

Paul received his BSc in Chemistry from the University of Nottingham and he then undertook PhD studies in synthetic organic chemistry at Nottingham with Professor G. Pattenden working on the total synthesis of marine natural products. Subsequently, he moved to the USA where he performed postdoctoral research with Professor E. J. Corey at Harvard University and then with Professor W. S. Johnson at Stanford University.

Paul started his career in drug discovery in 1994 as a medicinal chemist with Pfizer (Sandwich, UK) and through his research he has helped to co-discover and deliver a number of drug candidates across several therapeutic disease areas, some of which have gone on to advanced clinical studies. In 2006, he then combined his medicinal chemistry role with the position of Research Project Leader with the responsibility of delivering projects from the exploratory portfolio through to clinical FIH studies. In 2009, Paul joined the Regenerative Medicine and Epigenetic unit where he led the exploratory chemistry team in support of the unit’s small molecule and stem cell therapies with an emphasis on a chemogenomic approach towards phenotypical screening to identify new drug targets. In addition, he led Pfizer’s open access collaboration with the Structural Genomics Consortium to identify new chemical probes for epigenetic research.

In 2012 he was appointed as Professor and Chair of Medicinal Chemistry at the UCL School of Pharmacy where his research activities were focused on the identification of new small molecule chemical probes for bromodomain and histone methyl transferase proteins. In 2016, Paul moved to the UCL Faculty of Brain Sciences to become Head of Chemistry at the newly established Alzheimer's Research UK UCL Drug Discovery Institute. Most recently, he has been appointed as a Group Leader at The Francis Crick Institute where he has established a satellite research group.

Research Themes
Research Summary

Paul is Head of Chemistry at the Alzheimer’s Research UK UCL Drug Discovery Institute (ARUK UCL DDI).  Established in 2015, its goal is to facilitate the rapid translation of knowledge generated at UCL and partners towards novel therapeutics for neurodegenerative diseases: the dementias, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotropic lateral sclerosis.   The ARUK UCL DDI will consist of a team of ~ 25 chemists and biologists tasked with the goal of  developing and validating therapeutics for neurodegenerative diseases suitable for progression towards clinical trials.

Our website http://ucl-ddi.alzheimersresearchuk.org/

Teaching Summary

MSc in Drug Discovery and Development

MSc in Drug Discovery and Pharma Management

Please report any queries concerning the data shown on this page to https://www.ucl.ac.uk/hr/helpdesk/helpdesk_web_form.php
University College London - Gower Street - London - WC1E 6BT Tel:+44 (0)20 7679 2000

© UCL 1999–2011

Search by